TBL1X and osteosarcoma: BC2059, also known as Tegavivint, a disruptor of TBL1X binding, can overcome resistance to BET inhibitors and improve survival in human osteosarcoma and AML 8, 25, which suggests that BC2059 may be an effective drug for relevant tumor treatment.